Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.61 |
| ▸ | CA1 | P00915 | 3/20 | 0.61 |
| ▸ | CA2 | P00918 | 3/20 | 0.61 |
| ▸ | CA7 | P43166 | 3/20 | 0.61 |
| ▸ | CA9 | Q16790 | 3/20 | 0.61 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.61 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.61 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.61 |
| ▸ | CFTR | P13569 | 4/20 | 0.51 |
| ▸ | ESRRG | P62508 | 1/20 | 0.48 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | EGFR | P00533 | 2/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | MYC | P01106 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4563805 | 0.95 | CA12 (0.56) | CA12CA1CA2CA7CA9 | |
| SCHEMBL4563807 | 0.90 | CA12 (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL24436898 | 0.86 | CA12 (0.61) | CA12CA1CA2CA7CA9 | |
| SCHEMBL28516546 | 0.84 | CA12 (0.62) | CA12CA1CA2CA7CA9 | |
| SCHEMBL13948877 | 0.83 | CFTR (0.51) | CA12CA1CA2CA7CA9 | |
| SCHEMBL695717 | 0.83 | CFTR (0.51) | CA12CA1CA2CA7CA9 | |
| SCHEMBL10861732 | 0.83 | NOTUM (0.64) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2002005 | 0.83 | CFTR (0.69) | CA12CA1CA2CA7CA9 | |
| SCHEMBL22979384 | 0.81 | KDM4E (0.51) | CA1CA2CFTRNOTUMKDM4E | |
| SCHEMBL1458185 | 0.81 | GAA (0.60) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026088205-A1 | INHIBITORS OF SERINE PALMITOYLTRANSFERASE | INTONATION RESEARCH LABORATORIES PRIVATE LIMITED. (IN) | 2026-04-30 | — | — | WO | disclosed |
| US-12604895-B2 | Pesticidally active cyclic amine compounds | SYNGENTA CROP PROTECTION AG (CH) | 2026-04-21 | — | — | US | disclosed |
| US-20250282781-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2025-09-11 | — | — | US | disclosed |
| US-12403198-B2 | Benzimidazole thiophene derivative compounds inducing selective degradation of PLK1 | UPPTHERA (KR) | 2025-09-02 | — | — | US | disclosed |
| US-20250223286-A1 | IMMUNOMODULATORS, COMPOSITIONS AND METHODS THEREOF | BETTA PHARMACEUTICALS CO.,LTD (CN) | 2025-07-10 | — | — | US | disclosed |
| EP-4581017-A1 | NEW N-HETEROARYLBENZAMIDES DERIVATIVES AS FLT3 INHIBITORS | Biodol Therapeutics (FR) | 2025-07-09 | — | — | EP | disclosed |
| US-12344610-B2 | APOL1 inhibitors and methods of use | MAZE THERAPEUTICS, INC. (US) | 2025-07-01 | — | — | US | disclosed |
| EP-4561575-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | Cedilla Therapeutics, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| US-12187713-B2 | Immunomodulators, compositions and methods thereof | BETTA PHARMACEUTICALS CO., LTD (CN) | 2025-01-07 | — | — | US | disclosed |
| WO-2024249254-A2 | METHODS OF USING APOL1 INHIBITORS | MAZE THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| WO-2009091832-A1 | SYNTHESIS OF PYRAZOLES | WYETH (US) | 2009-07-23 | — | — | WO | disclosed |
| EP-2017263-A1 | HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2009-01-21 | — | — | EP | disclosed |
| EP-2017263-A1 | HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2009-01-21 | — | — | EP | disclosed |
| CN-101279971-A | 4,4-difluoro-1,2,3,4-tetrahydro-5h-1-benzoazepine derivative or salt of the same | ASTELLAS PHARMA INC (JP) | 2008-10-08 | — | — | CN | disclosed |
| CN-100404511-C | 4, 4-difluoro-1, 2,3, 4-tetrahydro-5H-1-benzazepine * derivatives or salts thereof | ASTELLAS PHARMA INC (JP) | 2008-07-23 | — | — | CN | disclosed |
| US-20070167429-A1 | 4,4-Difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine derivative or salt thereof | ASTELLAS PHARMA INC. | 2007-07-19 | — | — | US | disclosed |
| US-7183271-B2 | 4,4-difluoro-1,2,3,4-tetrahydro-5h-1-benzazepine derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2007-02-27 | — | — | US | disclosed |
| US-20060122170-A1 | 4,4-difluoro-1,2,3,4-tetrahydro-5h-1-benzazepine derivative or salt thereof | ASTELLA PHARMA INC. (JP) | 2006-06-08 | — | — | US | disclosed |
| CN-1780819-A | 4, 4-difluoro-1, 2,3, 4-tetrahydro-5H-1-benzazepine * derivatives or salts thereof | ASTELLAS PHARMA INC (JP) | 2006-05-31 | — | — | CN | disclosed |
| EP-1619185-A1 | 4,4-DIFLUORO-1,2,3,4-TETRAHYDRO-5H-1-BENZAZEPINE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2006-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250223286-A1 | IMMUNOMODULATORS, COMPOSITIONS AND METHODS THEREOF | IL2, IL5, TSLP | CA12 928/4885CA1 2975/4885CA2 3614/4885 |
| US-12344610-B2 | APOL1 inhibitors and methods of use | APOL1, APOB, PON1 | CA12 4394/4885CA1 4256/4885CA2 4457/4885 |
| US-20070167429-A1 | 4,4-Difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine derivative or salt thereof | SLC5A1, SLC5A2, DPP4 | CA12 2266/4885CA1 1412/4885CA2 685/4885 |
| US-12187713-B2 | Immunomodulators, compositions and methods thereof | IL2, TSLP, CD74 | CA12 1576/4885CA1 4067/4885CA2 4414/4885 |
| US-20060122170-A1 | 4,4-difluoro-1,2,3,4-tetrahydro-5h-1-benzazepine derivative or salt thereof | SLC5A1, SLC5A2, DPP4 | CA12 2266/4885CA1 1412/4885CA2 685/4885 |
| US-20250282781-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, PON1 | CA12 4394/4885CA1 4256/4885CA2 4457/4885 |
| US-12604895-B2 | Pesticidally active cyclic amine compounds | CLIC1, TUBA3C, CYCS | CA12 3462/4885CA1 1219/4885CA2 294/4885 |
| US-12403198-B2 | Benzimidazole thiophene derivative compounds inducing selective degradation of PLK1 | PLK1, BUB1, BUB1B | CA12 4665/4885CA1 4397/4885CA2 4502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.